Avance Clinical streamlines its biotech
clients' clinical trial operations, workflows, and data management,
optimizing study efficiencies, minimizing costs, and
accelerating trial timelines.
SAN
ANTONIO, Aug. 26, 2024 /PRNewswire/ -- Frost &
Sullivan recently assessed the biotech contract research
organization (CRO) industry and, based on its results, recognizes
Avance Clinical with the 2024 Global Customer Value Leadership
Award. The company is a leading CRO facilitating top-tier clinical
trials with globally recognized data for biotech firms worldwide.
With an exclusive focus on the biotech sector, the company
leverages over 30 years of deep clinical research experience across
more than 250 therapeutic indications to provide customized
services catering to biotech R&D's dynamic needs. Overall, the
company's world-class team, exceeding 330 clinical and regulatory
specialists, delivers high-quality clinical trials in Australia, New
Zealand, Asia, Europe, and North
America for international biotechs. As a full-service CRO,
it builds on its extensive expertise across various modalities
(ranging from small molecules to advanced cell therapies) to offer
sophisticated solutions covering the entire spectrum of drug
development, from preclinical stages through to Phase II/ III
studies.
![Avance Clinical comprehensively supports biotech clients through all clinical trial stages—including protocol development, site selection, patient recruitment, and data analysis—and eliminates the need to engage with multiple CROs. Avance Clinical comprehensively supports biotech clients through all clinical trial stages—including protocol development, site selection, patient recruitment, and data analysis—and eliminates the need to engage with multiple CROs.](https://mma.prnewswire.com/media/2489392/Avance_Clinical_Award_Logo.jpg)
Avance Clinical comprehensively supports biotech clients through
all clinical trial stages—including protocol development, site
selection, patient recruitment, and data analysis—and eliminates
the need to engage with multiple CROs. This streamlined approach
optimizes clinical study efficiencies, minimizes overall costs, and
accelerates trial timelines. Moreover, Avance Clinical, as a
midsized entity, embeds itself deeply into its biotech customers'
operations, with its scientific and regulatory consulting teams
engaging as early as possible to optimize their trial designs and
protocols. The company's flat organizational structure gives
customers direct access to leadership teams, facilitating continual
collaboration throughout their drug development journeys. Avance
Clinical's in-house regulatory team seamlessly integrates into
biotech clients' clinical and project delivery operations to
minimize delays and costly errors by up to 50% and 30%,
respectively.
Unmesh Lal, global research
director at Frost & Sullivan, observed, "Unlike larger
multinational CROs, this intimate approach enables Avance Clinical
to understand customer challenges closely, empowering it to deliver
flexible solutions and hands-on guidance that optimally position it
to match the fast-paced nature of biotech R&D. As a
result, the company's agility and responsiveness make it the ideal
partner for small to mid-sized biotech companies, addressing a
crucial need that competitors often struggle to fulfill."
Avance Clinical's in-house regulatory experts provide strategic
counsel on study design, regulatory compliance, and protocol
development, and they support customers' adaptability to rapidly
evolving regulatory landscapes. The company assists biotech
companies in achieving a 'clinic ready' status and offers a 'global
ready' roadmap for later phases, effectively transitioning biotech
products through the clinical development journey and towards
marketing authorization. Its high-quality, globally accepted
data empowers biotech clients to adequately address the sector's
increasing drug development complexities.
Avance Clinical's expansive network of over 2,000 high-quality,
trusted clinical trial sites ensures geographic diversity and a
wide patient population for each client. It facilitates quick
feasibility evaluations and rapid progression through start-up
activities, allowing for expedited patient recruitment and shorter
overall timelines. This ensures faster and more effective clinical
trials, including accelerated study start-up durations of five to
six weeks for early phase studies in Australia.
"Avance Clinical's customer focus, agility, and responsiveness
position it as the ideal contract research organization partner for
biotech customers. The company's globalization strategy, continual
scientific collaboration, unmatched regulatory expertise, and
personalization capabilities set it apart from its contemporaries.
Its overall customer-first approach offers immense value to
existing and new customers and solidifies Avance Clinical's
reputation in the market," added Sama
Suwal, best practices research analyst at Frost &
Sullivan.
Each year, Frost & Sullivan presents this award to the
company that has demonstrated excellence in implementing strategies
that proactively create value for its customers with a focus on
improving the return on the investment that customers make in its
services or products. The award recognizes the company's unique
focus on augmenting the value that its customers receive, beyond
simply good customer service, leading to improved customer
retention and customer base expansion.
Frost & Sullivan Best Practices awards recognize companies
in various regional and global markets for demonstrating
outstanding achievement and superior performance in leadership,
technological innovation, customer service, and strategic product
development. Industry analysts compare market participants and
measure performance through in-depth interviews, analyses, and
extensive secondary research to identify best practices in the
industry.
About Frost & Sullivan
For six decades, Frost & Sullivan has been world-renowned
for its role in helping investors, corporate leaders, and
governments navigate economic changes and identify disruptive
technologies, megatrends, new business models, and companies to
action, resulting in a continuous flow of growth opportunities to
drive future success. Contact us: Start the discussion. Contact us:
Start the discussion.
Contact:
Tarini Singh
P: +91 9953764546
E: tarini.singh@frost.com
About Avance Clinical
Avance Clinical is the largest
premium full-service Australian, Asian, and North American CRO
delivering quality clinical trials with globally accepted data for
international biotechs. The company's clients are biotechs
completing Phase I to Phase III of their drug development program
which requires fast, agile, and adaptive solution-oriented clinical
research services.
Frost & Sullivan Awards
Avance Clinical, a Frost & Sullivan Asia-Pacific CRO Market
Leadership Award recipient for the past four years, has been
providing CRO services in the region for more than 26 years.
Pre-clinical through to mid to late phase
Avance Clinical offers pre-clinical consulting and regulatory
services with their experienced ClinicReady team right from
pre-clinical and Phase I through to Phase III clinical services
leveraging significant Australian Government incentive rebates of
up to 43.5% and rapid start-up regulatory processes.
With experience across more than 250 indications, the CRO can
deliver world-class results and high-quality internationally
accepted data for TGA, FDA and EMA review.
Technology
Avance Clinical uses state-of-the-art technology and gold standard
systems across all functional areas to provide clients with the
most effective processes. Medidata, Oracle, TrialHub, Certinia,
Salesforce, Zelta and Medrio are just some of the technology
partners.
www.avancecro.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/frost--sullivan-awards-avance-clinical-for-global-biotech-cro-excellence-highlighting-agility-responsiveness-customer-value-and-proven-ability-to-expedite-quality-clinical-programs-302230335.html
SOURCE Frost & Sullivan